Results 91 to 100 of about 25,818 (186)

Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma. [PDF]

, 2017
The advent of genomics has led to the identification of specific "driver" mutations in oncogenic kinases, and the development of targeted small molecule inhibitors to block their tumor-driving functions.
Bivona, Trever G, Neel, Dana S
core   +1 more source

Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature

Diagnostic Pathology
Background Crizotinib, an oral first-generation tyrosine kinase inhibitor (TKI), is superior to systemic chemotherapy for the treatment of non-small cell lung cancer (NSCLC) with positive rearrangement of anaplastic lymphoma kinase (ALK).
Peng Zhang, JiaHua Xu, Qing Wu, Jianxin Qian, Song Wang   +4 more
doaj   +1 more source

Translation of Anticancer Efficacy From Nonclinical Models to the Clinic [PDF]

, 2014
Mouse cancer models have provided critical insights into tumor biology; however, clinical translation of these findings has been challenging. This perspective posits that factors impacting on successful translation start with limitations in capturing ...
Duda, D G, Stroh, M, Takimoto, C H, Vicini, P, Yamazaki, S   +4 more
core   +1 more source

Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report

BMC Cancer, 2020
Background Targeted therapies are a standard of care for first-line treatment of Anaplastic lymphoma kinase (ALK)-rearranged non small cell lung cancer (NSCLC).
F. Guisier, N. Piton, M. Bellefleur, N. Delberghe, G. Avenel, E. Angot, O. Vittecoq, M. Ould-Slimane, H. Morisse-Pradier, M. Salaun, L. Thiberville   +10 more
doaj   +1 more source

Health-related quality of life in KEYNOTE-010 : a phase II/III study of pembrolizumab versus docetaxel in patients with previously treated advanced, programmed death ligand 1-expressing NSCLC

, 2019
Introduction: In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1-expressing (tumor proportion score
Ahn, Myung-Ju, Barlesi, Fabrice, de Castro, Gilberto, Jr., Deitz, Anne C., Felip, Enriqueta, Fidler, Mary Jo, Garon, Edward B., Gubens, Matthew A., Han, Ji-Youn, Herbst, Roy S., Kim, Dong-Wan, Kim, Joo-Hang, Li, Qiao, Lubiniecki, Gregory M., Surmont, Veerle   +14 more
core   +1 more source

Biology of advanced uveal melanoma and next steps for clinical therapeutics [PDF]

, 2014
Uveal melanoma is the most common intraocular malignancy although it is a rare subset of all melanomas. Uveal melanoma has distinct biology relative to cutaneous melanoma, with widely divergent patient outcomes.
Bastian, BC, Bowcock, AM, Carvajal, RD, Flaherty, KT, Gershenwald, JE, Gutkind, JS, Luke, JJ, McKenna, KC, Patel, PM, Sato, T, Selig, S, Sossman, JA, Streicher, HZ, Sznol, M, Thurin, M, Triozzi, PL, Van Meir, EG, Welch, J   +17 more
core   +1 more source

The involvement of the Stat1/Nrf2 pathway in exacerbating Crizotinib-induced liver injury: implications for ferroptosis

Cell Death and Disease
Crizotinib carries an FDA hepatotoxicity warning, yet analysis of the FAERS database suggests that the severity of its hepatotoxicity risks, including progression to hepatitis and liver failure, might be underreported.
Lin Guo, JiaTing Ma, MingXuan Xiao, JiaYi Liu, ZhiYu Hu, Shuang Xia, Ning Li, Yan Yang, Hui Gong, Yang Xi, Rao Fu, Pei Jiang, ChunGuang Xia, Volker M. Lauschke, Miao Yan   +14 more
doaj   +1 more source

Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer. [PDF]

, 2018
Concurrent chemoradiation (cCRT) with platinum-based chemotherapy is standard-of-care therapy for patients with stage III unresectable non-small cell lung cancer (NSCLC).
Dicker, Adam P., Lu, Bo, McCall, Neal S.
core   +1 more source

Hubungan Kuantitatif Struktur Aktivitas Secara In Silico Senyawa 1-Benzil-3-benzoilurea dan Analognya Sebagai Antikanker Melalui Hambatan Reseptor ALK [PDF]

, 2017
Latar belakang: Reseptor ALK merupakan salah satu reseptor tirosin kinase untuk pembelahan sel, diferensiasi, dan antiapoptosis. Apabila ALK bermutasi, akan menyebabkan neuroblastoma, ALCL, IMT, NSCLC.
., Siswandono, Suhud, Farida, Wibowo, Bayu Sugio   +2 more
core  

Crizotinib Inhibits Viability, Migration, and Invasion by Suppressing the c-Met/PI3K/Akt Pathway in the Three-Dimensional Bladder Cancer Spheroid Model

Current Oncology
We aimed to evaluate the therapeutic potential of crizotinib, a broad-spectrum tyrosine kinase inhibitor against bladder cancer (BC) cells, based on a three-dimensional (3D) cell culture system.
Byeongdo Song, Danhyo Kim, Jin-Nyoung Ho, Van-Hung Le, Sangchul Lee   +4 more
doaj   +1 more source